Sugi Predict

Sugi Predict / Compounds / SCHEMBL931245

SCHEMBL931245

SCHEMBL931245

CC#Cc1cncc(Br)c1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 2/20 0.51
▸ CYP2A6 P11509 3/20 0.37
▸ POLB P06746 1/20 0.36
▸ HCAR2 Q8TDS4 1/20 0.36
▸ HTT P42858 3/20 0.33
▸ PRMT5 O14744 1/20 0.33
▸ WDR77 Q9BQA1 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ BACE1 P56817 2/20 0.32
▸ PTK2 Q05397 1/20 0.32
▸ ALOX15 P16050 1/20 0.32
▸ CTSD P07339 1/20 0.32
▸ PARP1 P09874 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10249638 0.86 GRM5 (0.47) GRM5CYP2A6POLBHCAR2HTT
SCHEMBL5742874 0.84 GRM5 (0.38) GRM5CYP2A6PRMT5WDR77BACE1
SCHEMBL15957833 0.79 GRM5 (0.40) GRM5CYP2A6PRMT5WDR77
SCHEMBL1477377 0.79 GRM5 (0.49) GRM5CYP2A6POLBHCAR2HTT
SCHEMBL8486570 0.78 GRM5 (0.47) GRM5CYP2A6POLBHCAR2HTT
SCHEMBL9948053 0.78 GRM5 (0.47) GRM5CYP2A6POLBHCAR2HTT
SCHEMBL14903886 0.76 GRM5 (0.51) GRM5CYP2A6HCAR2PRMT5WDR77
SCHEMBL1477046 0.75 GRM5 (0.55) GRM5HTTMAPTALOX15
SCHEMBL23181491 0.74 PRMT5 (0.33) GRM5CYP2A6PRMT5WDR77BACE1
SCHEMBL12938287 0.74 GRM5 (0.39) GRM5CYP2A6HCAR2PRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250002475-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS EPICS THERAPEUTICS (BE) 2025-01-02 — — US disclosed
US-12091400-B2 Piperidine derivatives as METTL3 inhibitors EPICS THERAPEUTICS (BE) 2024-09-17 — — US disclosed
US-20240270716-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS EPICS THERAPEUTICS (BE) 2024-08-15 — — US disclosed
US-20230212160-A1 2,4,6-TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AS ATR KINASE INHIBITORS BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) 2023-07-06 — — US disclosed
WO-2021050915-A1 MTA-COOPERATIVE PRMT5 INHIBITORS Mirati Therapeutics, Inc. (US) 2021-03-18 — — WO disclosed
US-10870635-B2 Compounds and their use as BACE1 inhibitors ALLGENESIS BIOTHERAPEUTICS, INC. (TW) 2020-12-22 — — US disclosed
US-10870635-B2 Compounds and their use as BACE1 inhibitors ALLGENESIS BIOTHERAPEUTICS, INC. (TW) 2020-12-22 — — US disclosed
CN-107613771-B Compounds and their use as beta-secretase 1 inhibitors 新源生物科技股份有限公司 2020-12-15 — — CN disclosed
EP-3176172-B1 SPIROIMIDAZOLE COMPOUNDS AND THEIR USE AS BACE INHIBITORS ASTRAZENECA AB (SE) 2020-01-29 — — EP disclosed
EP-3176172-B1 SPIROIMIDAZOLE COMPOUNDS AND THEIR USE AS BACE INHIBITORS ASTRAZENECA AB (SE) 2020-01-29 — — EP disclosed
US-7868000-B2 Aspartyl protease inhibitors SCHERING CORPORATION (US) 2011-01-11 — — US disclosed
US-7868000-B2 Aspartyl protease inhibitors SCHERING CORPORATION (US) 2011-01-11 — — US disclosed
WO-2011002407-A1 NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA ASTRAZENECA AB (SE) 2011-01-06 — — WO disclosed
WO-2011002407-A1 NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA ASTRAZENECA AB (SE) 2011-01-06 — — WO disclosed
WO-2011002408-A1 NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA ASTRAZENECA AB (SE) 2011-01-06 — — WO disclosed
WO-2011002408-A1 NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA ASTRAZENECA AB (SE) 2011-01-06 — — WO disclosed
WO-2010105179-A2 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. (US) 2010-09-16 — — WO disclosed
US-20070060575-A1 Aspartyl protease inhibitors MERCK SHARP & DOHME LLC 2007-03-15 — — US disclosed
US-20070060575-A1 Aspartyl protease inhibitors MERCK SHARP & DOHME LLC 2007-03-15 — — US disclosed
WO-2006138264-A2 ASPARTYL PROTEASE INHIBITORS SCHERING CORPORATION (US) 2006-12-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10870635-B2 Compounds and their use as BACE1 inhibitors BACE1, BACE2, APP GRM5 2445/4885CYP2A6 2311/4885POLB 481/4885
US-20070060575-A1 Aspartyl protease inhibitors CHRM2, BACE1, CHRM1 GRM5 1454/4885CYP2A6 1043/4885POLB 2334/4885
US-20240270716-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS METTL3, METTL16, DIMT1 GRM5 2318/4885CYP2A6 3441/4885POLB 847/4885
US-20250002475-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS METTL3, METTL16, DIMT1 GRM5 2318/4885CYP2A6 3441/4885POLB 847/4885
US-20230212160-A1 2,4,6-TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AS ATR KINASE INHIBITORS ATR, CHEK2, CHEK1 GRM5 3332/4885CYP2A6 2976/4885POLB 150/4885
US-12091400-B2 Piperidine derivatives as METTL3 inhibitors METTL3, METTL16, DIMT1 GRM5 2318/4885CYP2A6 3441/4885POLB 847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.